CURIS, INC.

CRIS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $9.4M $10.9M $10.0M $10.2M $10.6M $10.8M $10.0M $10.4M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development
SG&A Expense $14.0M $16.8M $18.6M $19.6M $17.3M $12.1M $11.6M $14.8M
Operating Income $-5.7M $-44.5M $-48.3M $-53.0M $-42.1M $-24.9M $-24.4M $-29.3M
Operating Margin -60.5% -408.3% -482.2% -521.7% -395.0% -229.8% -243.5% -281.3%
Interest Expense $0 $0 $791.0K $3.9M
Pretax Income
Income Tax Expense $0 $0
Net Income $-7.6M $-43.4M $-47.4M $-56.7M $-45.4M $-29.9M $-32.1M $-32.6M
Net Margin -80.3% -397.8% -473.0% -557.7% -426.7% -276.0% -321.3% -312.4%
EPS (Basic) $-0.58 $-3.44 $-4.48 $-6.07 $0.25 $-0.31 $-0.49 $-0.49
EPS (Diluted) $-0.58 $-3.44 $-4.48 $-6.07 $0.25 $-0.31 $-0.49 $-0.49
Shares Outstanding (Basic) 13.2M 12.6M 10.6M 9.3M 183.1M 97.3M 66.4M 66.3M
Shares Outstanding (Diluted) 13.2M 12.6M 10.6M 9.3M 183.1M 97.3M 66.4M 66.3M
Dividends Per Share
← Newer Page 1 of 3 Older →